


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

LISTING OF CLAIMS:

- 1-8. (cancelled)
9. (currently amended) A compound according to Formula IV.

**IV**

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H, -OR⁶, -S(O)₀₋₂R⁶, -N(R⁶)R⁷, -O-N(R⁶)R⁷, -N(R⁶)OR⁶, -N(R⁶)N(R⁶)R⁷, absent, oxo, thiono, and imino, ~~with the proviso that when X is oxo, thiono, or imino, there is only one R⁺;~~

R¹ and R², at each occurrence, are each independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

~~optionally, at least one pair of substituents, selected from two of R¹, one of R², and one each of R¹ and R², together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R⁺, each independently selected as defined above and optionally, two of R¹ when are paired,~~

together with the corresponding atom or atoms of the ~~first~~ ring to which they are attached, to form a second ring comprising between three and seven annular carbon atoms, said second ring optionally substituted with between zero and three of R^1 ;

R^3 is selected from -H and optionally substituted lower alkyl;

each of R^4 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl;

n is zero to four;

each R^5 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁷, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl; and

R^6 is -H or optionally substituted lower alkyl;

R^7 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl; and


R^6 and R^7 , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocycl ring, said optionally substituted five- to seven-membered heterocycl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

10. (withdrawn) The compound according to claim 9, wherein X is selected from -OR⁶, -SR⁶, and -N(R⁶)R⁷.

11. (withdrawn) The compound according to claim 10, wherein two of R^1 , together with the carbon or carbons to which they are attached, form said second ring.

12. (withdrawn) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R^1 .

13. (withdrawn) The compound according to claim 12, of formula V.




V

14. (withdrawn) The compound according to claim 13, wherein X is $-OR^6$.

15. (withdrawn) The compound according to claim 14, wherein R^3 is $-H$.

16. (withdrawn) The compound according to claim 15, wherein X is $-OH$.

17. (withdrawn) The compound according to claim 16, of formula VI.



VI

18. (withdrawn) The compound according to claim 17, wherein R^1 , R^4 , and R^5 are $-H$.

19-29. (cancelled)

30. (previously presented) A compound according to Table 3:

Table 3

#	Name	Structure
---	------	-----------

Table 3







#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4-amine	
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4-amine	
4	N-(cyclohexylmethyl)-2-pyridin-4-ylquinazolin-4-amine	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4-ylquinazolin-4-amine	
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin-4-ylquinazolin-4-amine	
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	

Table 3






#	Name	Structure
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
19	1,1-dimethylethyl 4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperidine-1-carboxylate	
24	3-[(2-pyridin-4-ylquinazolin-4-yl)amino]naphthalen-2-ol	
25	N-{4-[(1-methylethyl)oxy]phenyl}-2-pyridin-4-ylquinazolin-4-amine	

Table 3





#	Name	Structure
31	(1S,2R)-1-[(6-chloro-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
33	(1S,2R)-1-[(2-pyridin-3-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
45	(1S,2R)-1-[(6-bromo-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
46	(1S,2R)-1-[[6,7-bis(methoxy)-2-pyridin-4-yl]quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	

Table 3






#	Name	Structure
48	(1S,2R)-1-{{2-pyridin-4-yl-7-(trifluoromethyl)quinazolin-4-yl}amino}-2,3-dihydro-1H-inden-2-ol	
49	(1S,2R)-1-({2-[6-(methoxy)pyridin-3-yl]quinazolin-4-yl}amino)-2,3-dihydro-1H-inden-2-ol	
51	(1S,2R)-1-[(7-methyl-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
54	(2S)-3-methyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]butan-1-ol	
55	(2S)-2-phenyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]ethanol	

Table 3







#	Name	Structure
56	(2R)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
61	(2S)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
62	2-[(phenylmethyl)(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	

Table 3

#	Name	Structure
67	N-piperidin-1-yl-2-pyridin-4-ylquinazolin-4-amine	

31. (previously presented) A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.

32-38. (cancelled)